Tisotumab vedotin

Tisotumab vedotin (TV) is a humanized antibody-drug conjugate (ADC) directed against tissue factor, a protein involved in signaling pathways related to angiogenesis, cell adhesion, motility and survival. It has been reported that tissue factor is aberrantly expressed by many types of solid tumors and it is associated with negative oncological outcomes. ADCs combine monoclonal antibodies directed to surface antigens of specific tumor cells with highly potent anticancer agents linked via a chemical linker. After promising activity in vitro and in animal models, a multicenter, open-label phase I-II clinical trial (InnovaTV 201) reported an overall response rate of 15.6% and a median progression-free survival of 3 months in patients with solid advanced cancers who underwent TV therapy. In particular, a subanalysis demonstrated that TV had efficacy against cervical cancer with a good tolerability profile. Phase II clinical studies are ongoing to further investigate the efficacy and safety of TV as monotherapy or in combination with other targeted or cytotoxic drugs in patients with advanced cancer.